

PCMA MEMBER COMPANIES



Humana Pharmacy Solutions®



Medi**impact**



US**script**

PCMA

ANNUAL MEETING 2014

October 13 & 14

**TERRANEA RESORT
RANCHO PALOS VERDES, CA**

CONFERENCE PROGRAM

PARTNERS



PRESIDENTIAL SPONSORS

abbvie



PCMA WOULD LIKE TO THANK THE FOLLOWING COMPANIES FOR THEIR SUPPORT OF THE 2014 ANNUAL MEETING

PARTNERS



PRESIDENTIAL SPONSORS



EXECUTIVE SPONSORS



GENERAL SPONSORS



Welcome to the 2014 PCMA *Annual Meeting*

The PCMA *Annual Meeting* is the industry's premier executive conference. The event is tailored specifically for senior executives from PBMs and their affiliated business partners — most notably drug manufacturers. We've designed the *Annual Meeting* to be an important part of your business strategy and are proud of the unique value that the conference offers to PBM, specialty pharmacy and pharma industry executives.

The decision makers in attendance, educational insights and business opportunities are ultimately what make the *Annual Meeting* so valuable. There are many pressing issues impacting the health care industry today, key among them are cost and affordability. These and many other issues will be addressed both on and off the stage during the next two days. The interaction and dialogue that takes place at this event serves to promote continued industry collaboration addressing the many challenges we face.

We thank you for coming to this year's *Annual Meeting*. We hope that you find your time spent to be enlightening and beneficial to your business. Enjoy your time at Terranea.

Contents

Meeting Information	3
Private Meeting Room Assignments	4
Hotel Floor Plans and Maps.	5
Agenda	7
Session Details & Notes	11
Member Company Receptions	25
Speaker Bios	29
PCMA Board of Directors.	38
PCMA Staff	39
PCMA Members	40
PCMA Affiliates	41

a century of innovation

Nearly 100 years ago, Nobel Prize-winning scientist August Krogh and his wife Marie embarked on a journey to revolutionize diabetes care, driven by her needs as a diabetes patient. Today, Novo Nordisk still takes a deeply human approach to everything we do. As a world leader in diabetes care, we are in a position of great responsibility. We must continue to combine drug discovery and technology to turn science into treatments. We must prioritize research, education, and partnerships around the world to make diabetes a global priority. We must conduct our business responsibly in every way. And most importantly, we can never lose sight of the patient-centric approach that has driven our vision of innovation since our inception.

**Together, we can defeat diabetes
in our lifetime.**

For more about us, visit novonordisk-us.com



Meeting Information

Registration

All conference attendees are required to check in at the PCMA Registration Desk, located in the Terranea Conference Center on the Lobby Level.

Sunday, October 12	2:00 pm – 5:00 pm <i>Marineland Foyer</i>
Monday, October 13	7:00 am – 7:00 pm <i>Palos Verdes South Foyer</i>
Tuesday, October 14	7:00 am – 5:00 pm <i>Palos Verdes South Foyer</i>

Badges and conference materials will be available for pick up during these hours. Photo identification must be provided to collect your name badge and conference materials.

Blue badges indicate drug manufacturers; white badges indicate PBM, payer, specialty pharmacy and affiliate industries.

If you require a copy of your registration confirmation, receipt of payment, or invoice, please email Jenny Dawson at jdawson@pcmanet.org.

Conference Functions

Conference participants **MUST** wear badges when attending any conference activities including sessions, meals, evening receptions and private meetings in member and sponsor meeting room facilities. Event security will be monitoring entrances to all conference functions. Please do not misplace or forget badges, as duplicates will not be provided.

Attire

Attire for all conference activities is business casual. Some evening receptions will be held outdoors. Please be prepared for cooler temperatures.

Internet

To access the Internet or to print airline boarding passes, computer kiosks are available in the Palos Verdes West Foyer. Wi-Fi is not available in the hotel's conference center, but can be accessed while in the hotel lobby and other public spaces.

Presentations

It is at the discretion of each speaker to authorize distribution of their presentation slides. Please contact speakers directly to request slides or additional information.

Photography

Professional photographs taken during the conference may be posted online and printed in future materials.

Mobile/Smartphone Policy

As a courtesy to presenters and fellow attendees, mobile/smartphones should be turned to silent during all conference functions. Please minimize use during conference sessions.

Disclaimer

The opinions expressed by program participants are those of the individual speakers. They do not necessarily reflect the views of PCMA, its members or its affiliates.

Attendance at a Pharmaceutical Care Management Association (PCMA) meeting or event includes the limited, non-exclusive, revocable, and non-transferable right and license to use any PCMA materials, whether written, oral or electronic, made available by PCMA to the attendees for informational or personal use purposes only, PCMA reserves all other rights. PCMA or its licensors own all rights in and to all of its presentations, content, designs, methodologies, processes, programs, products, information and documentation. PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION, PCMA and all other names, logos and icons identifying PCMA and its products and services are proprietary trademarks of PCMA, and any use of such marks without the express written permission of PCMA is strictly prohibited.

Private Meeting Room Assignments

Please find all private meeting room assignments listed below. To help you locate these rooms, we have highlighted hotel floor plans and maps on the following pages. Please note that anyone entering meeting rooms must be registered for the conference and wearing a badge.


Contact Jenny Dawson, jdawson@pcmanet.org, with any questions related to private meeting space.

Partner & Presidential Sponsors	Meeting Room	Room Location within Hotel (see maps)
AbbVie	Bungalow 41-301 (ground floor)	Bungalow
Actavis	Bungalow 40-201 (top floor)	Bungalow
Allergan	Bungalow 41-101 (ground floor)	Bungalow
Astellas	Santa Cruz Boardroom	Sixth Floor Boardroom
AstraZeneca	Bungalow 43-101 (ground floor)	Bungalow
Baxter	Bungalow 40-301 (ground floor)	Bungalow
Bayer	Bungalow 43-401 (top floor)	Bungalow
Biogen Idec	Point Fermin	Second Floor Meeting Room
Boehringer Ingelheim	Bungalow 41-201 (top floor)	Bungalow
Celgene	Santa Barbara Boardroom	Sixth Floor Boardroom
EMD Serono	Inspiration Point	Second Floor Meeting Room
Genentech	Channel Islands Suite	Sixth Floor Boardroom
GlaxoSmithKline	Bungalow 43-201 (top floor)	Bungalow
Lilly USA, LLC	White's Point 2	Second Floor Meeting Room
Novartis	Bungalow 40-401 (top floor)	Bungalow
Novo Nordisk	Rocky Point 1	Second Floor Meeting Room
Sanofi	Bungalow 43-301 (ground floor)	Bungalow
Sunovion	Bungalow 41-401 (top floor)	Bungalow
Takeda	Bungalow 40-101 (ground floor)	Bungalow
Teva	Santa Rosa Boardroom	Sixth Floor Boardroom
Executive & General Sponsors	PCMA Members	
Acorda Therapeutics	Aetna	<p>Shared rooms are located amongst the second floor meeting rooms and the sixth floor boardrooms.</p> <p>Be sure to confirm the name of your meeting room with the meeting organizer.</p> <p>Please start and end meetings in shared rooms on time. Another meeting might immediately precede or follow yours.</p>
Actelion Pharmaceuticals	Catamaran	
Amgen	Cigna	
Auxilium	CVS Health	
CoverMyMeds	Express Scripts	
Daiichi Sankyo	Humana	
Eisai	LDI Integrated Pharmacy Services	
Gilead Sciences	MedImpact Healthcare Systems, Inc.	
Johnson & Johnson	OptumRx	
Lundbeck	Prime Therapeutics	
Mallinckrodt	US Script	
Merck		
Mylan		
Otsuka		
Pfizer		
Purdue Pharma L.P.		
Salix Pharmaceuticals, Inc.		
UCB		
Upsher Smith		
Valeant Pharmaceuticals		
Vertex		
Walgreens		

Hotel Floor Plans and Maps


Second Floor Meeting Rooms

The second floor meeting rooms are located on the ground floor of the Terranea Conference Center, one level below the conference general session hall (Palos Verdes 4 & 5) and the Marineland Ballrooms.



Sixth Floor Boardrooms

The sixth floor boardrooms are located on the sixth floor in the main hotel and can be accessed from guestroom elevators.



Bungalows

The bungalows are a very short walk outside from the conference center, just across the lawn and down a short flight of stairs.





Terranea Conference Center, Ballroom Level
(This is also the Lobby Level/Fourth Floor of the main hotel.)

Agenda

Monday, October 13

7:00 am – 7:00 pm	Registration Desk Open	<i>Palos Verdes South Foyer</i>
7:00 am – 5:30 pm	Private Meeting Rooms Open	<i>See page 4</i>
10:00 am – 11:00 am	<p>Annual Meeting Welcome</p> <p>Conference Moderator: Susan Dentzer, <i>Senior Policy Advisor</i> Robert Wood Johnson Foundation</p> <p>Federal and State Legislative and Regulatory Efforts to Control Patients' Cost Burden</p> <p>Lauren Barnes, <i>Senior Vice President, Avalere Health</i> Kristin Bass, <i>Senior Vice President, Policy and Federal Affairs</i> PCMA</p>	<i>Palos Verdes 4 & 5</i>
11:00 am – 11:30 pm	<p>PCMA Leadership Session — Strategic Insights and Priorities for the PBM Industry</p> <p>Mark Merritt, <i>President & Chief Executive Officer, PCMA</i> Dirk McMahon, <i>Chief Executive Officer, OptumRx</i> Jon Roberts, <i>President, CVS/caremark & Executive Vice President</i> CVS Health</p>	<i>Palos Verdes 4 & 5</i>
11:30 am – 12:00 pm	<p>Exchange Marketplace Report</p> <p>Peter Wickersham, <i>Senior Vice President, Integrated Care and Specialty, Prime Therapeutics</i></p>	<i>Palos Verdes 4 & 5</i>
12:00 pm – 1:15 pm	<p>Member Company Lunch Receptions (Concurrent)</p> <ul style="list-style-type: none"> » Aetna – <i>Palos Verdes 8</i> » Catamaran – <i>Palos Verdes Terrace</i> » CVS Health – <i>Marineland 3</i> » Express Scripts – <i>Marineland 1</i> » Humana – <i>Palos Verdes 7</i> » OptumRx – <i>Marineland 2</i> » Prime Therapeutics – <i>Palos Verdes 6</i> 	<i>See page 25</i>
1:30 pm – 2:00 pm	<p>Precision Medicine</p> <p>Roy Beveridge, MD, <i>Chief Medical Officer, Humana Inc.</i></p>	<i>Palos Verdes 4 & 5</i>
2:00 pm – 2:30 pm	<p>The Evolution of the Rx Channel and What it Means for PBMs</p> <p>Lisa Gill, <i>Managing Director, Senior Analyst, Equity Research, Healthcare Technology and Distribution, J.P. Morgan</i></p>	<i>Palos Verdes 4 & 5</i>
2:45 pm – 5:30 pm	Private Meeting Time	
5:30 pm – 7:30 pm	<p>Welcome Reception</p> <p><i>Attendees are invited to enjoy heavy hors d'oeuvres and cocktails.</i></p>	<i>Catalina Lawn & Terrace</i>

Tuesday, October 14

7:00 am – 5:00 pm	Registration Desk Open	<i>Palos Verdes South Foyer</i>
7:00 am – 8:00 pm	Private Meeting Rooms Open	<i>See page 4</i>
7:30 am – 8:30 am	Networking Breakfast	<i>Palos Verdes Lawn & Terrace</i>
8:30 am – 9:15 am	It's All About Value Tim Wentworth, <i>President</i> , Express Scripts	<i>Palos Verdes 4 & 5</i>
9:15 am – 10:00 am	Pharma Leadership Address — <i>The Price and Value of Curative Hepatitis C Medications</i> John Milligan, PhD, <i>President & Chief Operating Officer</i> Gilead Sciences	<i>Palos Verdes 4 & 5</i>
10:00 am – 10:30 am	Public Policy and the U.S. Health Care System Troy Brennan, MD, <i>Chief Medical Officer</i> , CVS Health	<i>Palos Verdes 4 & 5</i>
10:30 am – 11:15 am	PBMs, Specialty Pharmacies and Pharma Program Alignment — <i>Affordability, Adherence and Outcomes</i> Duane Barnes, <i>Chief Operating Officer</i> , Prime Therapeutics Mike Staff, <i>General Manager, National Accounts, Integrated Managed Health Care</i> , AbbVie	<i>Palos Verdes 4 & 5</i>
11:15 am – 11:45 pm	Payer Driven Specialty Management for the Future Alan Lotvin, MD, <i>Executive Vice President, CVS/specialty</i> CVS Health	<i>Palos Verdes 4 & 5</i>
11:45 am – 1:00 pm	Networking Lunch	<i>Palos Verdes Lawn & Terrace</i>
1:00 pm – 1:30 pm	Advancing Clinical Care in Specialty — <i>Aligned Incentives Between All Stakeholders</i> Brian Seiz, PharmD, <i>Vice President & General Manager, Specialty Solutions</i> , Express Scripts	<i>Palos Verdes 4 & 5</i>
1:30 pm – 2:00 pm	A Deeper Understanding of Payer and Patient Decisions Around Drug Management and Medication Consumption Chris Burns, <i>Vice President, Marketing</i> , Catamaran	<i>Palos Verdes 4 & 5</i>
2:00 pm – 8:00 pm	Private Meeting Time & Private Dinners	
8:00 pm – 11:00 pm	Cocktail & Dessert Reception <i>Attendees are invited to enjoy dessert and after-dinner cocktails.</i>	<i>Lobby Bar & Terrace</i>

Session Details & Notes

Innovating Healthcare

From Novel Medicines to Collaborative Relationships

Introducing—the **NEW** Astellas Health Systems



Astellas Health Systems is dedicated to delivering innovative products to and forming lasting relationships with our customers. Our support programs are designed to help customers achieve their objectives as we continue to focus on key therapeutic areas that impact their members:

- | Urology
- | Oncology
- | Transplantation
- | Cardiology
- | Anti-infectives

We've changed our look, but not our approach to providing customer-driven quality programs. We are Astellas Health Systems: **Improving Healthcare Together.**

Member Company Receptions

Overview

Select PCMA members host receptions exclusively for conference attendees from the drug manufacturer industry (designated by a blue badge). These Member Company Receptions bring together all attendees from each host company and offer excellent opportunities for networking and one-on-one interactions between PBM and pharma executives.

The Member Company Receptions will take place concurrently during lunch on Monday, October 13 from 12:00 pm until 1:15 pm.

Lunch will be served in the foyers outside of each reception space. Manufacturer attendees will be able to flow in and out of the individual receptions. Please note, in addition to manufacturers wearing blue badges, only employees of the host company are allowed in their respective reception rooms. Non PCMA members and manufactures are welcome to eat and network in the foyers only.



Participating Companies	Reception Locations
Aetna	<i>Palos Verdes 8</i>
Catamaran	<i>Palos Verdes Terrace</i>
CVS Health	<i>Marineland 3</i>
Express Scripts	<i>Marineland 1</i>
Humana	<i>Palos Verdes 7</i>
OptumRx	<i>Marineland 2</i>
Prime Therapeutics	<i>Palos Verdes 6</i>



Otezla[®]
(apremilast) 30mg tablets

For adult patients with active psoriatic arthritis

AN ORAL THERAPY WITH A DIFFERENT LOOK

- ◆ Intracellular PDE4 inhibitor
- ◆ Significantly improved ACR20 response
- ◆ Significantly improved swollen and tender joint counts
- ◆ Significantly improved dactylitis and enthesitis*

Otezla combines an efficacy and safety profile for the results you want^{1,2}

- ◆ Otezla was studied in 3 randomized, double-blind, placebo-controlled trials of similar design. 1493 adults with active psoriatic arthritis (≥3 swollen and ≥3 tender joints), despite prior or current DMARD¹ therapy, were randomized to placebo or Otezla 30 mg twice daily, after a titration period¹
- ◆ Patients who failed >3 small molecules or biologics or >1 biologic TNF blocker were excluded¹

- ◆ Study 1 – ACR20 responders at week 16 (primary endpoint): Otezla, 38%; placebo, 19%; $P = 0.0001$ ^{1,2}
- ◆ Significant ACR20 responses also seen with Otezla in Studies 2 and 3^{1,2}

*In patients with preexisting dactylitis and enthesitis.
¹Disease-modifying antirheumatic drug.

INDICATION

- ◆ Otezla[®] (apremilast) is indicated for the treatment of adult patients with active psoriatic arthritis

IMPORTANT SAFETY INFORMATION

Contraindications

- ◆ Otezla is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation

Warnings and Precautions

- ◆ Depression: Treatment with Otezla is associated with an

increase in adverse reactions of depression. During clinical trials, 1.0% (10/998) of patients treated with Otezla reported depression or depressed mood compared to 0.8% (4/495) treated with placebo; 0.3% (4/1441) of patients treated with Otezla discontinued treatment due to depression or depressed mood compared with none in placebo treated patients (0/495). Depression was reported as serious in 0.2% (3/1441) of patients exposed to Otezla, compared to none in placebo treated patients (0/495). Suicidal ideation and behavior were observed in 0.2% (3/1441) of

patients on Otezla, compared to none on placebo (0/495). Two patients who received placebo committed suicide compared to none on Otezla

- Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur



Otezla[®] is a registered trademark of Celgene Corporation.
 © 2014 Celgene Corporation 07/14 USII-APR130019



- ◆ **Weight Decrease:** Body weight loss of 5-10% was reported in 10% of patients taking Otezla and in 3.3% of patients taking placebo. Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla
- ◆ **Drug Interactions:** Apremilast exposure was decreased when Otezla was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (eg, rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended

Adverse Reactions

- ◆ Adverse reactions reported in at least 2% of patients taking Otezla, that occurred at a

frequency at least 1% higher than that observed in patients taking placebo, for up to 16 weeks (after the initial 5-day titration), were (Otezla%, placebo%): diarrhea (7.7, 1.6); nausea (8.9, 3.1); headache (5.9, 2.2); upper respiratory tract infection (3.9, 1.8); vomiting (3.2, 0.4); nasopharyngitis (2.6, 1.6); upper abdominal pain (2.0, 0.2)

Use in Specific Populations

- ◆ **Pregnancy and Nursing Mothers:** Otezla is Pregnancy Category C; it has not been studied in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether apremilast or its metabolites are present in human milk. Caution should

be exercised when Otezla is administered to a nursing woman

- ◆ **Renal Impairment:** Otezla dosage should be reduced in patients with severe renal impairment (creatinine clearance less than 30 mL/min); for details, see Dosage and Administration, Section 2, in the Full Prescribing Information

Please see Brief Summary of Full Prescribing Information on the following page.

References: 1. Otezla [package insert]. Summit, NJ: Celgene Corporation; 2014. 2. Data on file, Celgene Corporation.

Get the latest news at otezlapro.com

**Otezla**[®]
(apremilast) 30mg tablets

Rx Only

OTEZLA® (apremilast) tablets, for oral use

The following is a Brief Summary of the Prescribing Information; see Full Prescribing Information for complete product information.

INDICATIONS AND USAGE

OTEZLA® (apremilast) is indicated for the treatment of adult patients with active psoriatic arthritis.

CONTRAINDICATIONS

OTEZLA is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation [see *Adverse Reactions (6.1)*].

WARNINGS AND PRECAUTIONS

Depression: Treatment with OTEZLA is associated with an increase in adverse reactions of depression. During the 0 to 16 weeks placebo-controlled period of the 3 controlled clinical trials, 1.0% (10/998) of patients treated with OTEZLA reported depression or depressed mood compared to 0.8% (4/495) treated with placebo. During the clinical trials, 0.3% (4/1441) of patients treated with OTEZLA discontinued treatment due to depression or depressed mood compared with none in placebo treated patients (0/495). Depression was reported as serious in 0.2% (3/1441) of patients exposed to OTEZLA, compared to none in placebo treated patients (0/495). Instances of suicidal ideation and behavior have been observed in 0.2% (3/1441) of patients while receiving OTEZLA, compared to none in placebo treated patients (0/495). In the clinical trials, two patients who received placebo committed suicide compared to none in OTEZLA treated patients. Before using OTEZLA in patients with a history of depression and/or suicidal thoughts or behavior prescribers should carefully weigh the risks and benefits of treatment with OTEZLA in such patients. Patients, their caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and if such changes occur to contact their healthcare provider. Prescribers should carefully evaluate the risks and benefits of continuing treatment with OTEZLA if such events occur.

Weight Decrease: During the controlled period of the studies, weight decrease between 5-10% of body weight was reported in 10% (49/497) of patients treated with OTEZLA 30 mg twice daily compared to 3.3% (16/495) treated with placebo [see *Adverse Reactions (6.1)*]. Patients treated with OTEZLA should have their weight monitored regularly. If unexplained or clinically significant weight loss occurs, weight loss should be evaluated, and discontinuation of OTEZLA should be considered.

Drug Interactions: Co-administration of strong cytochrome P450 enzyme inducer, rifampin, resulted in a reduction of systemic exposure of apremilast, which may result in a loss of efficacy of OTEZLA. Therefore, the use of cytochrome P450 enzyme inducers (e.g. rifampin, phenobarbital, carbamazepine, phenytoin) with OTEZLA is not recommended. [see *Drug Interactions (7.1)* and *Clinical Pharmacology (12.3)*].

ADVERSE REACTIONS

Clinical Trials Experience in Psoriatic Arthritis: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The majority of the most common adverse reactions presented in Table 2 occurred within the first two weeks of treatment and tended to resolve over time with continued dosing. Diarrhea, headache, and nausea were the most commonly reported adverse reactions. The most common adverse reactions leading to discontinuation for patients taking OTEZLA were nausea (1.8%), diarrhea (1.8%), and headache (1.2%). The proportion of patients with psoriatic arthritis who discontinued treatment due to any adverse reaction was 4.6% for patients taking OTEZLA 30 mg twice daily and 1.2% for placebo-treated patients.

Table 2: Adverse Reactions Reported in ≥ 2% of Patients on OTEZLA 30 mg Twice Daily and ≥ 1% Than That Observed in Patients on Placebo For Up To Day 112 (Week 16)

Preferred Term	Placebo		OTEZLA 30 mg BID	
	Day 1 to 5 (N=495) n (%) ^c	Day 6 to Day 112 (N=490) n (%)	Day 1 to 5 (N=497) n (%)	Day 6 to Day 112 (N=493) n (%)
Diarrhea ^a	6 (1.2)	8 (1.6)	46 (9.3)	38 (7.7)
Nausea ^a	7 (1.4)	15 (3.1)	37 (7.4)	44 (8.9)
Headache ^a	9 (1.8)	11 (2.2)	24 (4.8)	29 (5.9)
Upper respiratory tract infection ^b	3 (0.6)	9 (1.8)	3 (0.6)	19 (3.9)
Vomiting ^a	2 (0.4)	2 (0.4)	4 (0.8)	16 (3.2)
Nasopharyngitis ^b	1 (0.2)	8 (1.6)	1 (0.2)	13 (2.6)
Abdominal pain upper ^b	0 (0.0)	1 (0.2)	3 (0.6)	10 (2.0)

^a Of the reported gastrointestinal adverse reactions, 1 subject experienced a serious adverse reaction of nausea and vomiting in OTEZLA 30 mg twice daily; 1 subject treated with OTEZLA 20 mg twice daily experienced a serious adverse reaction of diarrhea; 1 patient treated with OTEZLA 30 mg twice daily experienced a serious adverse reaction of headache.

^b Of the reported adverse drug reactions none were serious.

^c n (%) indicates number of patients and percent.

Other adverse reactions reported in patients on OTEZLA were hypersensitivity, weight decrease, frequent bowel movement, gastroesophageal reflux disease, dyspepsia, decreased appetite*, migraine, cough, and rash.

*1 patient treated with OTEZLA 30 mg twice daily experienced a serious adverse reaction.

DRUG INTERACTIONS

Strong CYP 450 Inducers: Apremilast exposure is decreased when OTEZLA is co-administered with strong CYP450 inducers (such as rifampin) and may result in loss of efficacy [see *Warnings and Precautions (5.3)* and *Clinical Pharmacology (12.3)*].

USE IN SPECIFIC POPULATIONS

Pregnancy: *Pregnancy Category C:* OTEZLA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Pregnancy Exposure Registry:** There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to OTEZLA during pregnancy. Information about the registry can be obtained by calling 1-877-311-8972.

Nursing Mothers: It is not known whether OTEZLA or its metabolites are present in human milk. Because many drugs are present in human milk, caution should be exercised when OTEZLA is administered to a nursing woman. **Pediatric use:** The safety and effectiveness of OTEZLA in pediatric patients less than 18 years of age have not been established. **Geriatric use:** Of the 1493 patients who enrolled in Studies PsA-1, PsA-2, and PsA-3 a total of 146 psoriatic arthritis patients were 65 years of age and older, including 19 patients 75 years and older. No overall differences were observed in the safety profile of elderly patients ≥ 65 years of age and younger adult patients < 65 years of age in the clinical studies. **Renal Impairment:** OTEZLA pharmacokinetics were not characterized in subjects with mild (creatinine clearance of 60-89 mL per minute estimated by the Cockcroft-Gault equation) or moderate (creatinine clearance of 30-59 mL per minute estimated by the Cockcroft-Gault equation) renal impairment. The dose of OTEZLA should be reduced to 30 mg once daily in patients with severe renal impairment (creatinine clearance of less than 30 mL per minute estimated by the Cockcroft-Gault equation) [see *Dosage and Administration (2.2)* and *Clinical Pharmacology (12.3)*]. **Hepatic Impairment:** Apremilast pharmacokinetics were characterized in subjects with moderate (Child Pugh B) and severe (Child Pugh C) hepatic impairment. No dose adjustment is necessary in these patients.

OVERDOSAGE

In case of overdose, patients should seek immediate medical help. Patients should be managed by symptomatic and supportive care should there be an overdose.

Manufactured for: Celgene Corporation, Summit, NJ 07901

OTEZLA® is a registered trademarks of Celgene Corporation.

Pat. www.celgene.com

©2014 Celgene Corporation, All Rights Reserved.

Speaker Bios



Duane Barnes
Chief Operating Officer
Prime Therapeutics

As Prime Therapeutics' Chief Operating Officer, Duane Barnes works to continually develop and implement strategies that improve Prime's day-to-day operations. He has overall responsibility for Prime's pharmacy benefit management service operations, including member services and contact centers, clinical review operations, pharmacy audit, network management, PrimeMail® and Prime Therapeutics Specialty Pharmacy™.

These channels all provide support for members to help them more easily access their medications and prescription information while directly connecting them to the best pharmacy benefit solutions.

Prior to joining Prime, Mr. Barnes served as senior vice president of Aetna Rx Home Delivery and Aetna Specialty Pharmacy. Prior to that, he was the executive director of corporate logistics, warehousing and transportation at Quest Diagnostics, and vice president and general manager at Medco Health Solutions.

Mr. Barnes received his bachelor's degree from West Virginia University and Master of Business Administration, strategic management, and Master of Science, global supply chain management, from Indiana University, Kelley School of Business.

Mr. Barnes is active on many industry advisory boards, including the Specialty Board of Directors for Pharmaceutical Care Management Association, the national association representing America's pharmacy benefit managers, and the National Association of Specialty Pharmacy (NASP)/Specialty Pharmacy Association of America (SPAARx), the largest national association dedicated to the interests of all individuals in the specialty pharmacy segment of healthcare. Additionally, Barnes serves on the editorial board of *Specialty Pharmacy Times*.



Lauren Barnes
Senior Vice President
Avalere Health

Lauren Barnes, Senior Vice President, provides strategic payer planning and public policy expertise to clients in the pharmaceutical and biotechnology industries to assist in the successful commercialization of their products. Ms. Barnes focuses on optimizing market access for specialty products, particularly those facing challenging benefit design issues.

Prior to joining Avalere, Ms. Barnes was Director of the Payment and Coverage Group at Amgen. Immediately prior to her time with Amgen, Ms. Barnes worked for the Centers for Medicare & Medicaid Services in the Coverage and Analysis Group and sat on the Healthcare Common Procedure Coding System panel.

Ms. Barnes has a BA in Public Health and an MHS in Health Care Policy from Johns Hopkins University. Ms. Barnes serves on the board of the Cancer Support Community, an international nonprofit dedicated to providing support, education and hope to people affected by cancer.



Kristin Bass
Senior Vice President, Policy and Federal Affairs
PCMA

Kristin Bass is the Senior Vice President of Policy and Federal Affairs at the Pharmaceutical Care Management Association. In this role, she leads PCMA's strategic development of the industry's federal legislative and regulatory policies. Ms. Bass joined PCMA from the Senate Finance Committee staff, where she served as Health Policy Advisor to Ranking Minority Member Chuck Grassley (R-IA), with responsibility for private plan options in Medicare and commercial insurance issues. Previously she was the Senior Vice President for Policy at the Healthcare Leadership Council, where she led efforts on health IT, privacy and quality improvement. Prior to that, she headed WellPoint, Inc.'s Federal Affairs office and before that, the federal lobbying team at the American Association of Health Plans (now AHIP).

Ms. Bass holds a BA and an MBA from Yale University.



Roy Beveridge, MD
Chief Medical Officer
Humana Inc.

Roy Beveridge, MD, joined Humana in June 2013 as Senior Vice President and Chief Medical Officer. He is responsible for developing and implementing Humana's clinical strategy, with an emphasis on advancing the company's integrated care delivery model, especially in the areas of quality and cost improvement. He reports directly to the President and Chief Executive Officer and is a member of the Executive Team, which sets the strategic direction for the company.

Previously, Dr. Beveridge served as Chief Medical Officer for McKesson Specialty Health, a Dallas-based subsidiary of McKesson Inc. Prior to McKesson's acquisition of US Oncology in 2010, he served as the Executive Vice President and Medical Director at US Oncology. Dr. Beveridge also was the Co-Director of the Bone Marrow Transplant Program at INOVA Fairfax Hospital in Falls Church, Virginia.

Dr. Beveridge earned a Bachelor of Arts degree from Johns Hopkins University and a medical degree from Cornell University Medical College. He completed his residency in internal medicine at University of Chicago Hospitals and his fellowship at Johns Hopkins Hospital.

Board certified in medical oncology and internal medicine, Dr. Beveridge has authored numerous articles on a wide range of medical topics such as hematology, stem cell transplantation and quality/value-based medical practice.



Troy Brennan, MD
Chief Medical Officer
CVS Health

Troyen A. Brennan, MD, MPH, is Executive Vice President and Chief Medical Officer of CVS Health. Prior to joining CVS Health, Dr. Brennan was Chief Medical Officer of Aetna Inc. From 2000 to 2005, Dr. Brennan served as President and CEO of Brigham and Women's Physician's Organization. In his academic work, he was Professor of Medicine at Harvard Medical School, and Professor of Law and Public Health at Harvard School of Public Health.

Dr. Brennan received his MD and MPH degrees from Yale Medical School and his JD degree from Yale Law School. He completed his internship and residency in internal medicine at Massachusetts General Hospital. He is a member of the Institute of Medicine of the National Academy of Sciences.



Chris Burns
Vice President, Marketing
Catamaran

Chris Burns is Vice President of Marketing at Catamaran. In his role, Mr. Burns is responsible for leading marketing strategy for all aspects of Catamaran's business including the management of Catamaran's market-facing value proposition, proposal operations and sales enablement, direct-to-consumer strategy and marketing, and all Voice of Customer research and measurement.

Mr. Burns came to Catamaran through the merger of Catalyst Health Solutions and SXC Health Solutions. At Catalyst, he served as Senior Vice President and Chief Marketing Officer and was responsible for managing the firm's overall marketing and communications operations including marketing, public relations, internal communications and corporate communications.

Prior to joining Catalyst, Mr. Burns worked at The Cosmopolitan of Las Vegas where he served as the Director, Content & Entertainment Curation. In that role, he drew upon his wealth of experience building and positioning brands to curate The Cosmopolitan's unique guest experience and bring a differentiated resort offering to the Las Vegas market. The branding and experiential design efforts he led were brought to life across all aspects of the resort's operations through details like the content displayed on more than 500 digital screens throughout the property, the music selection in the casino and restaurant uniforms and menus. His work at The Cosmopolitan has been awarded the Gold Design Pencil at the One Show and the prestigious Grand Prix Design Lion at the Cannes Lions International Festival of Creativity.

Mr. Burns' other experience includes management roles at top marketing agencies and consultancies including Arthur Andersen Consulting, Edelman and Prophet Brand Strategy where he has led brand strategy, internal communications, customer segmentation, innovation and strategy articulation projects. He has worked in a variety of industries including health care, financial services, agriculture, consumer products and hospitality.

Mr. Burns holds an MBA from the University of Chicago Booth School of Business with concentrations in Strategy, Marketing Management, International Business and Entrepreneurship and a bachelor's degree in International Marketing from American University. He currently serves on the Board of Directors for Snow City Arts, a nonprofit organization focused on bringing bedside arts education to hospitalized children and has studied improvisational comedy at The Second City Training Center in Chicago.



Susan Dentzer
Senior Policy Advisor
Robert Wood Johnson Foundation

Susan Dentzer is Senior Policy Adviser at the Robert Wood Johnson Foundation, the nation's largest health and health care philanthropy, based in Princeton, New Jersey. In this role, she works closely with foundation leaders to carry out the organizational mission of improving the health and healthcare of all Americans. One of the nation's most respected health and health policy thought leaders and journalists, she is also an on-air analyst on health issues on the PBS *NewsHour*.

Ms. Dentzer is an elected member of the Institute of Medicine and the Council on Foreign Relation, and a fellow of both the National Academy of Social Insurance, a nonprofit, nonpartisan organization made up of the nation's leading experts on social insurance, and the Hastings Center, an institution dedicated to bioethics and public interest. She is also a public trustee of the American Board of Medical Specialties, the not-for-profit organization that oversees 24 approved medical specialty boards in setting standards for board certification and maintenance of certification for the nation's physicians, and a member of the board of directors of Research!America, which advocates for increased U.S. investment in biomedical research.

Ms. Dentzer is a frequent guest and commentator on such National Public Radio shows as *This American Life* and *The Diane Rehm Show*. From May 2008 to April 2013, Ms. Dentzer was the Editor-in-Chief of *Health Affairs*, the nation's leading journal of health policy, where she transformed the journal from a bimonthly academic publication to a highly readable and topical monthly journal and online publication with more than 120 million page views annually.

Prior to joining the journal, Ms. Dentzer was an on-air correspondent on health and health policy for the *PBS NewsHour with Jim Leher*, where she earned numerous awards for her work. (The unit was supported by a grant from the Robert Wood Johnson Foundation.) Before joining the *NewsHour*, Ms. Dentzer served as chief economics correspondent and economics columnist for *US News & World Report* and as a senior writer for *Newsweek*.

Ms. Dentzer has been the recipient of several fellowships, including the Nieman Fellowship for journalists at Harvard University and the U.S.-Japan Leadership Program fellowship sponsored by the Japan Society of New York.

Ms. Dentzer is also a member of the Board of Overseers of the International Rescue Committee, a humanitarian organization providing relief to refugees and displaced persons around the world. She chairs the IRC board's Program Committee, which oversees the organization's activities in resettling refugees in the United States and in dealing with refugees and displaced persons in roughly 25 countries. Dentzer has served on IRC commissions examining the problems of domestic violence against women in West Africa and, in 2007, the situation of Iraqi refugees in Syria and Jordan.

A graduate of Dartmouth and holder of an honorary master of arts from the institution, Ms. Dentzer is a Dartmouth trustee emerita, and was the only woman to date to chair the Dartmouth Board of Trustees, which she did from 2001 to 2004. Winner of the Dartmouth Alumni Award, the Young Alumni Award and the Dartmouth Presidential Medal for Achievement, she has served on the Board of Overseers of Dartmouth Medical School since 1993.

Ms. Dentzer, her husband and their three children live in the Washington, DC area.



Lisa Gill

Managing Director, Senior Analyst, Equity Research, Healthcare Technology and Distribution

J.P. Morgan

Lisa Gill has been a leading member of the healthcare equity research team for 16 years. She is highly regarded on Wall Street for her in-depth analysis and management relationships. She is a Certified Public Accountant and has over twenty years of diversified healthcare experience. She has been a Senior Publishing Analyst in since June 2000, and currently is responsible for coverage of 17 companies within healthcare services including healthcare distribution, PBMs, drug retail, healthcare information technology, clinical labs and institutional pharmacy sectors.

She began her career with Ernst & Young's audit group specializing in health care facilities where she earned her CPA. She then worked in Coopers & Lybrand's healthcare services consulting group specializing in physician and long-term care reimbursement. She was a Director of Development at Health Partners where she acquired physician practices in New York City prior to joining J.P. Morgan.



Alan Lotvin, MD

Executive Vice President, CVS/specialty CVS Health

Alan M. Lotvin, MD, is Executive Vice President of Specialty Pharmacy for CVS Health. In this role, Dr. Lotvin has overall responsibility for the company's Specialty Pharmacy business, a rapidly growing division of the company's pharmacy benefits management business. He is focused on driving specialty pharmacy strategy and identifying opportunities for growth and innovation in this fast-growing segment of the health care industry.

Dr. Lotvin is a published author with an extensive clinical background and experience in the health care services, pharmaceutical benefit management and specialty pharmacy industries. Prior to joining CVS, Dr. Lotvin was President and Chief Executive Officer of ICORE Healthcare, a Magellan Health Services company. Previously, he has held roles as President and Chief Operating Officer of MIC Communications, a leading medical education provider. After leaving clinical practice, Dr. Lotvin served in various senior management roles at Medco Health Solutions, including serving as President of Medco Specialty Pharmacy Services.

Dr. Lotvin began his career as an interventional cardiologist in the New York metropolitan area with a faculty appointment at College of Physicians and Surgeons at Columbia University.

Dr. Lotvin holds a master's degree in Medical Informatics from Columbia University and a Medical Degree from the State University of New York Health Sciences Center in Brooklyn.



Dirk McMahon
Chief Executive Officer
OptumRx

Dirk McMahon currently serves as Chief Executive Officer for OptumRx. In this capacity, his primary responsibilities include overseeing UnitedHealth Group pharma benefit management programs, including pharmacy network, mail service, specialty pharmacy and Diabetes ActiveCareSM services.

Mr. McMahon joined UnitedHealth in 2003, holding various management positions in Information Technology, Operations and Finance. Prior to his current position, he served as President and CEO of UnitedHealthcare Benefit Operations. Before joining UnitedHealthcare, Mr. McMahon was head of airport operations worldwide for Northwest Airlines for 19 years.

Mr. McMahon received a Bachelor of Science degree in finance from Marist College and a Masters in Business Administration (MBA) in finance from the University of Notre Dame. He serves on the board of directors for Bridging, a nonprofit organization in Minneapolis that provides families and individuals transitioning out of homelessness and poverty with furniture and household goods to improve their lives.



Mark Merritt
President & Chief Executive Officer
PCMA

Mark Merritt is President and Chief Executive Officer of the Pharmaceutical Care Management Association, the national association representing America's pharmacy benefit managers. PBMs drive prescription drug costs lower for more than 200 million Americans and manage about 70 percent of the more than three billion prescriptions dispensed in the United States each year.

Mr. Merritt took the helm of PCMA in March 2003 and quickly raised the industry's profile in Washington. *National Journal* noted that a "new player has appeared on the field among the associations in Washington's health care lobbying game" and named Mr. Merritt one of the most influential players in the Medicare prescription drug debate. Mr. Merritt is also repeatedly ranked as one of the most effective trade association CEOs in America by *The Hill* newspaper in Washington, DC.

Mr. Merritt is credited with designing and implementing innovative, campaign-focused strategies that go beyond traditional Washington-style lobbying campaigns. Mr. Merritt has pioneered strategies that reach beyond the boundaries of Washington politics to communicate more effectively with diverse constituencies from Wall Street to Main Street and even Hollywood.

Mr. Merritt has served as a senior strategist with America's Health Insurance Plans and the Pharmaceutical Research and Manufacturers of America (PhRMA) as well as with the presidential campaigns of current U.S. Senator Lamar Alexander and former Senator Robert Dole. Mr. Merritt has also served as a Fellow at Harvard University's John F. Kennedy School of Government, where he lectured on the intersection of public policy and the news media.

He holds both an MA and BA from Georgetown University. He and his wife Jayne have four children.



John Milligan, PhD
President & Chief Operating Officer
Gilead Sciences

Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008.

Dr. Milligan was named “Bay Area CFO of the Year” in 2006 for companies with revenues greater than \$500 million, and he was named the top biotechnology industry CFO in the United States by *Institutional Investor* magazine in 2006, 2007 and 2008. Dr. Milligan is a member of the boards of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization, and Pacific Biosciences of California, Inc. He is also a Trustee of Ohio Wesleyan University.

Dr. Milligan received his BA from Ohio Wesleyan University, his PhD in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.



Jon Roberts
President, CVS/caremark & Executive Vice President
CVS Health

Jonathan C. Roberts is Executive Vice President of CVS Health and President of CVS/caremark, the company’s Pharmacy Benefit Management business. In this role, Roberts and his team are focused on reinventing pharmacy in order to help the company’s PBM clients improve health care outcomes for their members while managing overall health care costs. Roberts also demonstrates a strong commitment to delivering excellent client service driven by a high level of quality process development and execution.

Mr. Roberts has more than 30 years of pharmacy health care experience. He has developed a reputation as a results-driven leader, whose analytical approach has enabled him to successfully lead a diverse array of initiatives across the organization.

Mr. Roberts previously served as Chief Operating Officer of the PBM business, supporting the company’s efforts to build a world-class infrastructure designed to address the changing needs of its PBM clients and their members. In that role, he was responsible for PBM and Specialty Pharmacy Operations, Trade and Pharmaceutical Purchasing, Underwriting and PBM Networks. Prior to that role, he was EVP of Pharmaceutical Purchasing, Pricing and Network Relations and also served as the company’s Chief Information Officer, where he spearheaded several key programs, including the Pharmacy Service Initiative (PSI), which significantly enhanced pharmacy performance at CVS/pharmacy, and was highlighted in business case studies at the Harvard Business School and Yale School of Management. He also served as Senior Vice President of Retail Store Operations, following 20 years in retail field management positions.

Mr. Roberts earned his degree in pharmacy from the Virginia Commonwealth University School of Pharmacy. He is a member of the Pharmaceutical Care Management Association’s Board of Directors, as well as the Norman Prince Neurosciences Institute’s Advisory Council.



Brian Seiz, PharmD
Vice President & General Manager, Specialty Solutions
Express Scripts

As Vice President and General Manager of Specialty Solutions, Brian Seiz, PharmD, leads the team responsible for developing innovative solutions to ensure the best use of specialty medications to improve patient health outcomes at lower client costs. These responsibilities include:

- » Leading the Formulary and Utilization Management programs for Express Scripts
- » Creating the clinical care model for Accredo Specialty Pharmacy
- » Driving Accredo specialty solutions product innovation
- » Managing physician and client sales teams and supporting account management for Accredo specialty solutions

Dr. Seiz joined Express Scripts in January 2004 as Director of Medicare Clinical Programs. He has served in a variety of different leadership roles across the clinical and specialty areas of Express Scripts, Specialty Benefit Services, CuraScript Specialty Pharmacy and Accredo Specialty Pharmacy, but has always focused on how the proper use of medications can improve health outcomes for patients at a lower cost for clients.

Prior to joining Express Scripts, Dr. Seiz spent six years as an assistant professor of Pharmacy Practice at St. Louis College of Pharmacy. There, he taught two key components in Pharmacy curriculum: drug information and evaluation of medical literature. He also maintained a clinical practice in primary care during his years with St. Louis College of Pharmacy.

Dr. Seiz received his Doctorate of Pharmacy from St. Louis College of Pharmacy and fulfilled his primary care residency at John Cochran VA.



Mike Staff
General Manager, National Accounts, Integrated Managed Health Care
AbbVie

Mike Staff assumed his current role as General Manager, National Accounts of Managed Healthcare in August of 2013. In his current role, Mr. Staff is responsible for leading the development of contracting strategy, brand strategy and execution of all marketing programs for all contracted U.S. pharmaceutical products into managed care channels.

Prior to his current role, Mr. Staff held various positions at AbbVie, including Director of Sales, Marketing Director (Synthroid and Creon), National Managed Care Executive and Senior Product Manager. Prior to joining AbbVie, Mr. Staff worked in a series of roles at both United Healthcare and Searle/Pharmacia.

Mr. Staff received a Bachelor of Science in marketing from Northern Illinois University.



Tim Wentworth
President
Express Scripts

As President, Express Scripts, Tim Wentworth has management responsibility for all aspects of the company's core business. This includes sales and account management, as well as information technology, operations, research and new solutions, and supply chain management.

Mr. Wentworth joined Express Scripts in 2012 as Senior Vice President and President, Sales and Account Management. Prior to coming aboard, he led the employer and key accounts organizations at Medco Health Solutions for nearly 14 years. Before Medco, Mr. Wentworth spent five years at Mary Kay, Inc., where he served initially as Senior Vice President of Human Resources and subsequently as President, International. He also spent nine years in human resources management at Pepsi Co. Mr. Wentworth was promoted to President of Express Scripts in 2014.

In 2006, Mr. Wentworth took a two-year break from his role in account management to serve as president and CEO of Accredo, where he led the rapid and successful integration of Accredo into the broader Medco organization.

With 15 years of executive PBM experience, Mr. Wentworth is a well respected leader in his field. He has been a featured speaker at Harvard University, the U.S.-Russia business council, the American Management Association, and the Best 100 Companies Symposium. Mr. Wentworth uses his industry expertise and experience to push Express Scripts' sales and account management teams to consistently exceed client expectations.

Mr. Wentworth holds a BS in Industrial and Labor Relations from Cornell University and an AS of Business from Monroe Community College.



Peter Wickersham
Senior Vice President, Integrated Care and Specialty
Prime Therapeutics

As Prime Therapeutics' Senior Vice President of Integrated Care and Specialty, Peter Wickersham has accountability for effectively managing \$14 billion in annual prescription drug spend across all segments of Prime's commercial and government business. With the integration of medical and pharmacy care at the center of Prime's value proposition, Wickersham has focused Prime's cost of care efforts beyond traditional pharmacy benefit management to address key areas of clinical quality such as drug adherence in high risk populations, gaps in care, as well as the care of patients requiring complex specialty medications.

Mr. Wickersham currently manages Prime's clinical, trade relations, outcomes research, specialty and enterprise reporting and analytics teams. From 2012 to mid-2014, he was also accountable for the retail pharmacy networks and pharmacy audit organizations at Prime. Mr. Wickersham has a wealth of experience in many aspects of pharmaceuticals and pharmacy management, including clinical research, product development, contract negotiations, statistical analysis, information technology and operations.

He most recently served as vice president of operations at CIGNA Pharmacy Management and prior to that as a principal in Mercer's pharmacy practice and as the vice president of manufacturer relations and product development for Aetna.

After studying pre-medicine as an undergraduate, Wickersham received a master's degree in Applied Statistics and a master's degree in Nuclear Science and Engineering from Louisiana State University. In addition, he has an Executive Masters in Technology Management from the University of Pennsylvania.

Mr. Wickersham serves on the board of directors for Pharmacy Quality Alliance, an organization committed to improving the quality of medication use across health care settings, and an editorial advisory board for a leading publication company serving the health care industry.

PCMA Board of Directors



Chairman, PCMA Board of Directors

Dirk McMahon
Chief Executive Officer
OptumRx



**Vice Chairman and Incoming Chairman,
PCMA Board of Directors**

Jon Roberts
*President, CVS/caremark &
Executive Vice President*
CVS Health



Ren Elder
*President, Aetna Pharmacy
Management*
Aetna



George Paz
*Chairman &
Chief Executive Officer*
Express Scripts



Eric Elliott
*President &
Chief Executive Officer*
Prime Therapeutics



Mark Thierer
*Chairman & Chief Executive
Officer*
Catamaran



William Fleming
*President, Humana Pharmacy
Solutions*
Humana Inc.



Greg Watanabe
President
MedImpact Healthcare
Systems, Inc.



Chris Hocesvar
*President, Select Segment &
Cigna Pharmacy Management*
Cigna Corporation

PCMA Staff

Mark Merritt

President & Chief Executive Officer

Kristin Bass

Senior Vice President, Policy and Federal Affairs

Tim Brogan

Assistant Vice President, Public Affairs and Policy

Andy Cosgrove

Vice President, Policy

Charles Cote

Vice President, Strategic Communications

Clem Cypra

Assistant Vice President, State Affairs

Jenny Dawson

Manager, Conferences and Development

Jonathan Heafitz

Senior Director, Federal and Regulatory Affairs

Ryan Hickey

Director, Accounting and Operations

Greg Johnson

*Assistant Vice President,
Federal and Regulatory Affairs*

Jennifer Joslin

*Executive Assistant to the
President & Chief Executive Officer*

Wendy Krasner

Vice President, Regulatory Affairs

Barbara Levy

Vice President & General Counsel

Greg Lopes

Director, Public Affairs

Jessica Mazer

Assistant Vice President, State Affairs

Brian McCarthy

Chief Operating Officer

Anne McCraw

Senior Director, Industry Relations

Brenda Palmer

Chief Financial Officer

Kristen Pumphrey

Senior Director, Conferences

Meagan Riordan

Manager, State Affairs

Jerry Steffl

Vice President, Federal Affairs

Deloris Tinsley

Executive Assistant

PCMA Members

aetna[®]



Humana Pharmacy Solutions[®]



Mediimpact



USscript

PCMA Affiliates





*we bring high
quality medicines
to patients around
the world*

Teva Pharmaceuticals is working every day to make quality healthcare accessible around the world. As a manufacturer of specialty and generic pharmaceuticals, Teva provides both new therapies and greater access to quality, affordable medicines. For more information, please visit tevausa.com

TEVA

MORE THAN 40 YEARS IN
SPECIALTY
CARE

Where science is aimed at
difficult-to-treat diseases,
like multiple sclerosis
and cancer

EMDSerono



EMDSerono

SOLVING THE WORLD'S TOUGHEST HEALTH CHALLENGES TAKES ALL OF US.

It takes the will to find a new way forward.
And no one gets there alone.

That's why AbbVie teams with peers, academics,
clinical experts and others to take on the most
complex health challenges.

Uniting the best of pharma with the boldness
of biotech, together we're going beyond
conventional thinking to innovate end-to-end
approaches that make a real difference.

Starting with science, we arrive at solutions
that help millions of patients around the
world live better.

[Learn more at abbvie.com](http://abbvie.com)

AbbVie focuses on:

LIVER DISEASE

IMMUNOLOGY

NEUROSCIENCE

ONCOLOGY


KIDNEY DISEASE

WOMEN'S HEALTH



PEOPLE. PASSION.
POSSIBILITIES.

abbvie



Proud Sponsor of the PCMA Annual Meeting 2014

As a leading global specialty pharmaceutical company, Actavis is committed to improving the health of patients around the world. As part of this commitment, we deliver important medicines that help healthcare providers treat diseases principally in the central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory and anti-infective therapeutic categories.

About Actavis

Actavis (NYSE:ACT), including its Forest Laboratories subsidiary, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.

www.Actavis.com

www.FRX.com

 Actavis



 **Forest Laboratories, LLC**



**Medical
Dermatology**



Eye Care



Neurosciences



**Medical
Aesthetics**

Many disciplines. One vision.

Allergan Managed Markets
unites our strengths in multiple
therapeutic areas to optimize
life's potential.




Urologics

 **ALLERGAN**
Managed Markets

Many disciplines. One vision.

©2013 Allergan, Inc., Irvine, CA 92612
APC26PA13



What does AstraZeneca stand for? **Diversity**

AstraZeneca is committed to discovering medicines that are safe and effective.

Scientists rely on clinical trials to develop new medicines. But African Americans and Hispanics are often underrepresented in clinical trials. AstraZeneca launched a partnership with the National Medical Association and the Interamerican College of Physicians and Surgeons to recruit minority physicians who can help make sure that all Americans are represented.

A commitment to diversity. That's what AstraZeneca stands for.

www.AZandMe.com

AstraZeneca 



Creating a better today and tomorrow for patients

Baxter's employees are united in a mission to save and sustain lives. We are passionate about applying scientific innovation to meet the needs of the millions of people worldwide who depend on our medically necessary therapies and technologies. We focus on increasing access to healthcare, innovating in crucial areas of unmet need, and pursuing creative collaborations that bring our mission to life for patients every day.

Baxter

baxter.com



**MOTIVATED
TO MAKE
AN
IMPACT?** | **AT BAYER
YOU'RE
EXPECTED
TO BE.**

Bayer is an international science-based company that is inspired to impact the future and improve the way people live in our world. As a global corporate citizen, we make every effort to contribute to society with innovations that improve


life now and in the future. As part of the Bayer team, you are empowered to find answers to questions addressing the great challenges of our time, and make a tangible impact with your ideas and solutions.



Passion to innovate | **Power to change**

Science For A Better Life

Nurturing innovative ideas today for more health tomorrow.



Boehringer Ingelheim ranks among the world's 20 leading pharmaceutical corporations. Our vision drives us forward. It helps us to foster value through innovation in our company and to look to the future with constantly renewed commitment and ambition.

For more than 125 years, Boehringer Ingelheim has been committed to the research and development of innovative medicines that help make more health for patients and their families.

Visit us online at
us.boehringer-ingelheim.com





Caring Deeply. Changing Lives.™

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.

Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company.

www.biogenidec.com

biogen idec®

To us, science is personal.

At Genentech, we're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That's why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal.

Find out more at gene.com

Elaine, patient

Genentech
A Member of the Roche Group

To us, science is personal.

At Genentech, we're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That's why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal.

Find out more at gene.com

Nicolas, patient

Genentech
A Member of the Roche Group



**Creating
Better**

CONNECTIONS

Today's healthcare system is an incredibly complex matrix, connecting patients, providers, payers, and products. At Lilly, we are continually looking for innovative ways to connect the right medicines to the right patients and build better connections across the continuum of care.

With a 130-year tradition of innovation and collaboration, we are committed to creating better connections to help diagnose and treat chronic diseases such as diabetes, depression, or osteoporosis. It's our way of connecting the dots and working together for better health.



MANAGED
HEALTHCARE
SERVICES

MH85706 0713 Printed in USA.
©2013, Lilly USA. All rights reserved.



***Dedicated to helping you
provide affordable, high-quality
Biopharmaceuticals***



Call your Account Manager for more information,
or reach us at http://sandoz.com/tools/contact_us/
and we will have your Account Manager contact you

© 2014 Sandoz Inc. All Rights Reserved.

OMNI0574 10/2014



MANAGED MARKETS

Alcon[®]

A difference your plan can see

Partner with Alcon Managed Markets

Our leading pharmaceuticals and exceptional eye care products come with an understanding of your business. Ask your Alcon Managed Markets account manager to see more.

©2013 Novartis 09/13 MGC13205MS

a Novartis company



SANOFI

A DIVERSIFIED GLOBAL HEALTHCARE LEADER,
FOCUSED ON PATIENTS' NEEDS

Our strategy is based on three key principles: **increasing innovation in R&D, seizing external growth opportunities and adapting the company's model to future challenges and opportunities.**

Sanofi has core strengths in healthcare, with 6 growth platforms: **emerging markets, vaccines, consumer healthcare, diabetes treatments, innovative products and animal health.** Through the acquisition of Genzyme, Sanofi has reinforced its footprint in biotechnology and rare diseases. With approximately 110,000 employees in 100 countries, Sanofi and its partners act to **protect health, enhance life and respond to the potential healthcare needs of the 7 billion people around the world.**

For more information:

www.sanofi.com - www.sanofi.us - www.facebook.com/sanofiUS - <http://twitter.com/sanofiUS>

COR.11.02.007



SUNOVION


Healthy bodies, healthy lives

A new energy in the search
for advanced pharmaceuticals.

Sunovion Pharmaceuticals Inc. is a leading pharmaceutical company dedicated to discovering, delivering and commercializing therapeutic products that advance the science of medicine and improve the lives of patients with central nervous system diseases and respiratory ailments.

Sunovion Pharmaceuticals Inc.

Visit us at www.sunovion.com



Working in Partnership with You

www.takeda.us

Takeda Pharmaceuticals U.S.A., Inc.

89201



We Offer More Than Face Time.

If you haven't heard, GSK is moving forward by aligning our actions with managed care executives' expectations. This means we are continuously investing in the strategic expertise of our account managers to *understand your needs*.

Difficult challenges, such as improving population outcomes, abound for managed care organizations—and that's where the account managers at GSK can *bring together experts who offer credible scientific and economic knowledge* that can provide insights to inform your solutions.

True collaboration is more than face time—it's moving forward with *solutions that meet your needs*.

©2013 The GlaxoSmithKline Group of Companies
All rights reserved. Printed in USA. January 2013



Transforming the language of life into vital medicines.

At Amgen we use our deep understanding of human biology to address the unmet needs of patients fighting serious illness to dramatically improve their lives. For more information about our pioneering science and vital medicines, visit www.amgen.com.

AMGEN[®]

Pioneering science delivers vital medicines[™]



©2011 Amgen Inc. All rights reserved.


covermymeds®



350+
Integrated EHRs



72%
of Payor Market



45,000+
Integrated Pharmacies

The only prior authorization vendor
integrated in the clinical workflow

REALIZE THE BENEFITS. BECOME A PARTNER. covermymeds.com | 866-452-5017

Passion for Innovation.
Compassion for Patients.™



With a legacy of over 100 years of scientific expertise, Daiichi Sankyo is a global pharmaceutical company with corporate origin in Japan.

Building on our experience of innovation in the areas of cardiovascular diseases and bacterial infections, Daiichi Sankyo is expanding into other important therapeutic areas where significant unmet medical needs remain, such as the development of medicines for blood clot and stroke prevention, cancer treatments, and medicines for diabetes and related conditions.

Today, through a growing presence in emerging markets, we are pleased to meet the needs of patients in more than 50 countries around the world.

Discover more at
WWW.DSI.COM



Passionate about patient care

Eisai's passionate commitment to patient care is the driving force behind our efforts to find innovative solutions that help address unmet medical needs and contribute to the well-being of patients worldwide. With therapies in oncology and specialty care, we focus on having an impact on patients and their families. At Eisai, *human health care* is our goal.



h/hc
human health care

CORP0400 ©2014 Eisai Inc. All rights reserved. July 2014 www.eisai.com/us



Advancing Therapeutics, Improving Lives.

For more than 25 years, Gilead has been committed to developing medicines that address areas of unmet medical need for people around the world.

Our portfolio of medicines and pipeline of investigational drugs include treatments for HIV/AIDS, hepatitis, serious respiratory and cardiovascular conditions, cancer and inflammation.

Every day we strive to transform and simplify care for people with life-threatening illnesses.


For more information, please visit www.gilead.com.
© 2013 Gilead Sciences, Inc.



Johnson & Johnson HEALTH CARE SYSTEMS INC.

Johnson & Johnson Health Care Systems Inc. (JJHCS), a Johnson & Johnson company, provides contracting, supply chain and business services to key health care customers, including hospital systems and group purchasing organizations, leading health plans, and government health care institutions, in the United States. This ability to partner with many different customer groups makes JJHCS essential to the success of the Johnson & Johnson Family of Companies.

Through its Customer Service Centers, JJHCS touches customers of the Johnson & Johnson Family of Companies more than 9,500 times per day. The company manages countless electronic orders for products via its "e" channels. JJHCS executes contracted sales—1.2 million orders—for several U.S. medical device companies. JJHCS also processes customer rebates and chargebacks on behalf of U.S.-based Johnson & Johnson Medical Devices & Diagnostics, Pharmaceutical and Consumer companies.



MEDICAL BREAKTHROUGHS MAY COME OUT OF THE LAB. BUT THEY BEGIN IN THE HEART.

For more than 150 years, a very special passion has driven the people of Merck. Our goal is to develop medicines, vaccines, consumer care and animal health innovations that will improve the lives of millions. Still, we know there is much more to be done. And we're doing it, with a long-standing commitment to research and development. We're just as committed to expanding access to healthcare and working with others who share our passion to create a healthier world. Together, we'll meet that challenge. With all our heart.



For more information about getting Merck medicines and vaccines for free, visit merckhelps.com or call 800-727-5400.
Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All Rights Reserved. CORP-1060080-0006 01/13



How is one company working to meet the needs of 7 billion people?

Discover how, at Mylan, we are providing high quality medicine to the world's population.

Mylan.com

 **Mylan**[®]
Seeing
is believing


Anita completed her first of many triathlons at age 57.

Pfizer developed **Get Old** to challenge us to rethink aging and take a more active role in our health.


At Pfizer, we make medicines and vaccines that extend and improve lives, yet we know that medicines alone cannot give you a healthy life.

It's time to challenge how we think about aging and look forward to what's yet to come.

To learn more, visit GetOld.com.







Decisions that fit Programs that matter Solutions that count

A privately held pharmaceutical company founded by physicians, Purdue is dedicated to meeting the needs of our Managed Care partners by developing programs that improve both patient care and patient safety:

- **PartnersAgainstPain.com** offers people living with pain, as well as their friends and families, comprehensive and clear information on a wide variety of pain issues
- **RxSafetyMatters.org** is an online resource for healthcare professionals, law enforcement, and community organizations to help combat the illegal diversion and abuse of prescription medications

Proud sponsors of



THE PARTNERSHIP
AT DRUGFREE.ORG



PurduePharma.com

©2012 Purdue Pharma L.P., Stamford, CT 06901-3431 B8248-HP 3/12



We have a **One Tract** mind.

Advancing Treatment in Gastroenterology

We are committed to providing products that treat and help diagnose gastrointestinal diseases.



For questions, please call **1-866-669-SLXP (7597)**

www.salix.com

©2013 Salix Pharmaceuticals, Inc.

MCOSAL 13/01



THE SCIENCE *of* POSSIBILITY

Vertex creates new possibilities in medicine to cure diseases and improve people's lives.

We work with leading researchers, doctors, public health experts and other collaborators who share our vision for transforming the lives of people with serious diseases, their families and society.

www.vrtx.com

© 2014 Vertex Pharmaceuticals Incorporated 9/14



Since its founding in 1999, Auxilium Pharmaceuticals has been committed to researching and developing biopharmaceuticals for underdiagnosed conditions with unmet treatment needs.

We are committed to supporting your efforts and your patients.

Learn more about our company at www.auxilium.com.

COR-00052



Lundbeck is a pharmaceutical company committed to improving the lives of those suffering from psychiatric and neurological disorders.

We support and participate in hundreds of community awareness and educational events each year. This participation fuels our passion to make a difference, one patient at a time.

To learn more about Lundbeck, visit www.lundbeckus.com.

UBR-D-00077



WHERE OTHERS SEE COMPLEX PROBLEMS, MALLINCKRODT SEES UNIQUE SOLUTIONS

Today's Mallinckrodt Pharmaceuticals combines more than 146 years of expertise with the determined focus needed to solve the complex specialty pharmaceutical challenges of today. Whether it's the production of medicines for pain or ADHD, the development of drugs that treat CNS conditions, or providing patients with hospital-based analgesia treatment options, we are working to make complex products simpler, safer and better for patients.

Learn more at www.mallinckrodt.com



Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2014 Mallinckrodt.



People creating new products
for better health worldwide



The name "Otsuka" translates to "major milestone."

And indeed, for over 85 years, Otsuka's people have achieved major milestones in their quest to create new products for better health. Otsuka is hard at work investigating potential new treatments, with numerous compounds in various stages of development to treat disorders of the cardiovascular, gastrointestinal, respiratory, renal, and central nervous systems, and to treat cancer and ophthalmic disorders. We've funded new research, supported new clinical trials, and pursued the development of new medications – an unfaltering commitment of energy and resources with one goal in mind – to create new products for better health worldwide.

1.800.562.3974
www.otsuka-us.com

Otsuka America Pharmaceutical, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Maryland Medicinal Laboratories, Inc.

© 2014 Otsuka America Pharmaceutical, Inc.

February 2014 01US14EUP0002

ADVANCING PHARMACOTHERAPY
IMPROVING LIFE



SEEING EAR TO EAR

Only by listening will a vision for managing CNS diseases emerge.

Let's ask questions.

Let's actively listen to all insights, ideas, and opinions.

And once we start talking, let's keep the conversation going.

For when we understand what patients and their caregivers want, and fully recognize the many ways clinicians and scientists can contribute, the possibilities will become endless.

For nearly 100 years, the solutions offered by Upsher-Smith have come from seeing things differently and hearing another point of view. And we're not stopping here. We now ask that you join us on this journey of discovery. What we learn together may surprise, challenge, and ultimately transform what it means to live with CNS disease.

Visit upsher-smith.com to learn more.

UPSHER-SMITH
Partners in Health Since 1919



The specialty pharmacy provider of choice for cost-effective care.



Our patient-focused strategies saved one health plan \$28.5 million over two years.¹

Our clinical and utilization management programs help your members get the care, access and savings they need. Let our team of more than 70,000 healthcare professionals help you improve patient outcomes and control your specialty pharmacy spend.

**For more information, call 877-727-9247
or visit WalgreensHealth.com/Business.**

Walgreens

1. Baldini CG, Culley EJ. Estimated cost savings associated with the transfer of office-administered specialty pharmaceuticals to a specialty pharmacy provider in a medical injectable drug program. *J Manag Care Pharm.* 2011;17:51-59.



A DIVISION OF THE
Pharmaceutical Care
Management Association

BUSINESS FORUM 2015

sPCMA Business Forum **March 16 & 17** **HILTON BONNET CREEK | ORLANDO, FL**

The *sPCMA Business Forum* is a business networking and educational conference designed for professionals of all levels engaged in the business of specialty pharmacy and pharmaceutical care. The *Business Forum* is designed to be an essential component of your annual conference schedule and business strategy.

From an educational standpoint, our speakers are among the industry's top thought leaders. When it comes to networking and conducting business with industry partners, the *Business Forum* attracts the highest number of PBM and specialty pharmacy senior executives and decision makers of any industry conference.

Conference features include:

- » **Remarks by C-suite and other senior PBM, specialty pharmacy and pharma executives**
- » **25+ timely and thought-provoking educational sessions** — more than **10 hours of CPE** sessions offered
- » Dedicated **time and facilities for private meetings**
- » **Pre-conference networking through *PCMA-Connect***, a LinkedIn Group and online networking community for PCMA's PBM members, affiliates and registered conference attendees to connect and stay connected before, during and after the event
- » **10+ networking receptions**, including invitation-only events for members, affiliates and conference sponsors

WHO SHOULD ATTEND

The *sPCMA Business Forum's* 1,200+ attendees range from C-suite executives to mid-level professionals tasked with all aspects of the business of specialty pharmacy and overall pharmaceutical care and will include specialty pharmacies of all sizes and composition, PBMs and payers, manufacturers, wholesalers, distributors, investors, consultants, vendors and other suppliers.

REGISTRATION WILL OPEN IN NOVEMBER



ANNUAL MEETING 2015

PCMA Annual Meeting **September 21 & 22**

THE BROADMOOR | COLORADO SPRINGS, CO

The *PCMA Annual Meeting* is the industry's premier executive conference. The event provides an unmatched and ideal venue for senior executives from PBMs, specialty pharmacy, payer organizations and pharmaceutical manufacturers to network, conduct business and learn about the most current issues impacting the industry.

The decision makers in attendance, educational insights and business connections made while on-site are ultimately what make the *Annual Meeting* so successful. The high level interactions that take place at this event help to promote continued industry collaboration and dialogue addressing participants' aligned objectives.

WHO SHOULD ATTEND

The *Annual Meeting* is designed specifically for PBM, specialty pharmacy, payer and pharma and biotech executives. Registration for this event is restricted. Only PCMA members and affiliate sponsors are guaranteed registration slots for this event.

REGISTRATION WILL OPEN FOR ELIGIBLE PARTICIPANTS IN JUNE 2015

Please contact Jenny Dawson to learn more about the Affiliate Program, sponsorship opportunities, registration, housing and other general conference inquiries.

Jenny Dawson
Manager, Conferences and Development
jdawson@pcmanet.org
202.756.7214



**601 Pennsylvania Avenue, NW
Suite 740, South Building
Washington, DC 20004
202.207.3610**

www.pcmnet.org